Evaluating AI in Healthcare: Implementing Approaches

By Sumona Bose

March 7, 2024

Introduction

Artificial intelligence (AI) holds great potential in healthcare by enhancing clinical decision-making and patient outcomes. However, a significant gap exists between the development of AI models and their successful integration into clinical practice. Despite the proliferation of AI-based clinical decision support systems (AICDSS), only a meager 2% of these models progress beyond the prototyping stage, leaving the actual clinical impact largely unexplored.

Evaluating Clinical Value through Rigorous Trials

The evaluation of AICDSS through randomised controlled trials (RCTs) stands as a critical step in determining their true clinical value. While some RCTs have been conducted, their outcomes paint a nuanced picture. Although these trials showcase promising statistical performance of AI, nearly half of them fail to demonstrate improved patient outcomes. This discrepancy underscores the complexity of assessing AI solely based on quantitative metrics like accuracy. This may not capture the practical utility of these systems in real-world healthcare settings. Table 1 unpacks the definitions associated with interpreting the patient outcomes. This helps clinicians and researchers shift from the arbitrariness that hinders real-world settings.

Reported in N (%)
Implementation outcomea Clinical explanation Implementation stage RCTs (N = 64) Guidelinesb (N = 5)
Appropriateness Is the AI compatible with the clinical workflow and is it useful? Early 5 (8) 0 (0)
Acceptability Is the AI acceptable, agreeable, or satisfactory for the users? Ongoing 10 (16) 0 (0)
Feasibility Can the AI be successfully used as intended by the manufacturer? Early 16 (25) 0 (0)
Adoption Do the users express the initial decision, or action to try or employ the AI? Ongoing 6 (9) 0 (0)
Fidelity Is the AI implemented as intended by the manufacturer? Ongoing 31 (48) 0 (0)
Implementation cost What is the cost impact of implementing the AI system? Late 4 (6) 0 (0)
Penetration Has the AI been adopted by all groups of trained users? Late 0 (0) 0 (0)
Sustainability Is the AI maintained within ongoing clinical operations over time? Late 1 (2) 0 (0)

Table 1: AI in RCTs, Definitions of implementation outcomes were adapted from the taxonomy of implementation outcomes by Proctor et al (2011). 

The Need for a Holistic Evaluation Approach

A comprehensive understanding of AI’s role in clinical practice necessitates a multi-faceted evaluation strategy. Current guidelines like Developmental and Exploratory Clinical Investigations of DEcision support systems driven by Artificial Intelligence (DECIDE-AI) and Consolidated Standards of Reporting Trials–Artificial Intelligence (CONSORT-AI), fall short in providing robust measures for assessing AI implementation success. To address this gap, a mixed-methods evaluation approach,  proves invaluable in dissecting the various dimensions of AICDSS implementation.

Bridging the Gap in Implementation Evaluation

Despite the increasing focus on RCTs evaluating AICDSS in clinical settings, a gap exists in the comprehensive evaluation of implementation outcomes.  While metrics like ‘fidelity’ are commonly reported using quantitative measures, aspects such as ‘acceptability’ and ‘appropriateness’ that demand qualitative scrutiny are often overlooked. This imbalance underscores the need for a more holistic approach towards evaluating the implementation of AICDSS, encompassing factors beyond statistical performance. Figure 1 reiterates the comprehensive value of integrating implementation outcomes in AI in healthcare, revealing an innovative future in the field.

figure 2
Figure 1: a In the current situation, AI-CDSS, are clinically deployed, after going through multiple preclinical validations (e.g., external and temporal algorithm validation) to assess their clinical utility and effectiveness. b To enhance comprehension of factors that contributed to successful implementation or failure at the bedside, implementation outcomes should be systematically integrated in future clinical trials evaluating AICDSS in real-world clinical settings. *Implementation outcomes as described by Proctor et al.

Conclusion

While the efficacy of AICDSS in healthcare settings is crucial, understanding the contextual nuances is imperative. Enhanced systematic reporting of implementation outcomes alongside effectiveness metrics can bridge the existing gap in comprehensively assessing the impact of clinical AI. Embracing an inclusive evaluation framework will not only validate the effectiveness of AICDSS but also shed light on the intricate interplay between AI technology and healthcare delivery.

Reference url

Recent Posts

EU Life Sciences Strategy
         

EU Life Sciences Strategy: Paving the Way for Europe’s Leadership by 2030

🚀 Is Europe poised to reclaim its leadership in life sciences by 2030?

The European Commission has unveiled a game-changing strategy aimed at transforming the EU into the world’s leading hub for life sciences, tackling critical challenges in health, biotechnology, and sustainability. With strategic investments and reforms, this initiative promises to bridge the innovation gap and enhance public health outcomes across the continent.

Curious about how these plans will impact the life sciences landscape? Explore the full insights of this exciting strategy!

#SyenzaNews #HealthcareInnovation #DigitalTransformation #Innovation

ticagrelor data integrity
          

Ticagrelor Data Integrity Under Fire: Scrutiny Reveals Flaws in Key Clinical Trials

🔍 Are we truly getting the full story on high-cost medications like ticagrelor?

A recent BMJ investigation has raised alarm bells over the integrity of data from pivotal studies on AstraZeneca’s ticagrelor, revealing significant misreporting and missing data that may undermine its clinical benefits. This exposes critical implications for health economics, regulatory oversight, and market access.

Curious about how these findings could reshape perceptions of drug efficacy and safety? Dive into the full article to uncover the truth behind the numbers.

#SyenzaNews #HealthEconomics #Pharmaceuticals #MarketAccess

self-care public health
    

The Value of Self-Care in Public Health: Insights and Implications for Europe

🌍 Are we overlooking the power of self-care in Europe’s public health strategy?

The rise of self-care public health is reshaping how minor ailments are managed across the continent, leading to remarkable economic and productivity benefits. With annual savings of €36 billion and lifestyle improvements for consumers, self-care is proving to be a game-changer for healthcare systems.

Explore how embracing self-care can alleviate pressure on healthcare providers and enhance individual well-being. Dive into the full article to discover the implications for health economics and public policy!

#SyenzaNews #HealthEconomics #HealthcarePolicy

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.